These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17194504)

  • 21. Etiology and pathophysiology of portal hypertension.
    Reichen J
    Z Gastroenterol; 1988 Sep; 26 Suppl 2():3-7. PubMed ID: 3055716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Portal hypertension and blood viscosity.
    Sikuler E
    J Clin Gastroenterol; 2007; 41 Suppl 3():S262-5. PubMed ID: 17975475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Splanchnic and systemic vasodilation: the experimental models.
    Wiest R
    J Clin Gastroenterol; 2007; 41 Suppl 3():S272-87. PubMed ID: 17975477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Splanchnic and systemic vasodilatation: the patient.
    Tsai MH
    J Clin Gastroenterol; 2007; 41 Suppl 3():S266-71. PubMed ID: 17975476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
    Matei V; Rodríguez-Vilarrupla A; Deulofeu R; García-Calderó H; Fernández M; Bosch J; Garcia-Pagán JC
    J Hepatol; 2008 Aug; 49(2):192-7. PubMed ID: 18534709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Turnes J; Bellot P; Deulofeu R; Abraldes JG; Bosch J
    Hepatology; 2006 Mar; 43(3):485-91. PubMed ID: 16496307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Portal hypertension and angiogenesis].
    Stumm M; Sieber C
    Schweiz Med Wochenschr; 2000 Feb; 130(7):233-9. PubMed ID: 10719714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of portal hypertension.
    Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pathogenesis of portal hypertension].
    Montaño-Loza A; Meza-Junco J
    Rev Invest Clin; 2005; 57(4):596-607. PubMed ID: 16315644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of glucagon improves splanchnic hyporesponse to terlipressin in cirrhotic rats with blood retention in the gastric lumen.
    Yang YY; Lin HC; Huang YT; Hou MC; Lee FY; Chang FY; Lee SD
    J Hepatol; 2005 May; 42(5):652-8. PubMed ID: 15826713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender differences in vascular reactivity of mesenteric arterioles in portal hypertensive and non-portal hypertensive rats.
    Zhang B; Ji LH; Zhang CG; Zhao G; Wu ZY
    World J Gastroenterol; 2019 Oct; 25(39):5953-5960. PubMed ID: 31660032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Underlying mechanism of portal hypertensive gastropathy in cirrhosis: a hemodynamic and morphological approach.
    Curvêlo LA; Brabosa W; Rhor R; Lanzoni V; Parise ER; Ferrari AP; Kondo M
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1541-6. PubMed ID: 19743998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Portal hypertension: state of the art.
    Gatta A; Sacerdoti D; Bolognesi M; Merkel C
    Ital J Gastroenterol Hepatol; 1999 May; 31(4):326-45. PubMed ID: 10425579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension.
    Moleda L; Jurzik L; Froh M; Gäbele E; Hellerbrand C; Straub RH; Schölmerich J; Wiest R
    World J Gastroenterol; 2010 Apr; 16(15):1837-44. PubMed ID: 20397260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of bile acids in splanchnic hemodynamic response to chronic portal hypertension.
    Thomas SH; Joh T; Benoit JN
    Dig Dis Sci; 1991 Sep; 36(9):1243-8. PubMed ID: 1893807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
    Shah V
    J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenergic response of splanchnic arteries from cirrhotic patients: role of nitric oxide, prostanoids, and reactive oxygen species.
    Salcedo A; Garijo J; Monge L; Fernández N; García-Villalón AL; Turrión VS; Cuervas-Mons V; Diéguez G
    Exp Biol Med (Maywood); 2007 Nov; 232(10):1360-7. PubMed ID: 17959849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylaxis with ketotifen in rats with portal hypertension: involvement of mast cell and eicosanoids.
    Sanchez-Patan F; Anchuelo R; Vara E; Garcia C; Saavedra Y; Vergara P; Cuellar C; Rodero M; Aller MA; Arias J
    Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):383-94. PubMed ID: 18693174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does local sympathetic atrophy contribute to splanchnic vasodilation in portal hypertension?
    Møller S; Stauber RE
    Liver Int; 2010 Apr; 30(4):499-501. PubMed ID: 20158609
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.